| Trial | Name |
| 0C-03-6 | A Phase I Trial of 5-Aza-2’-Deoxycytidine (DAC) and Sodium Phenylbutyrate in Patients with Solid Tumors. |
| 0C-04-3 | Phase I Trial of Intravenous Fenretinide (4-HPR) for Patients with Hematologic Malignancies. |
| 0C-04-8 | A Phase I Study of VEGF-Antisense Oligonucleotide (VEGF-AS) Given as Daily and Three Times a Week Fixed Dose Subcutaneous Injection in the Treatment of Patients with Relapsed or Refractory Malignancies. |
| 0C-05-5 | A Phase I Trial of PXD101 in Combination with 13-cis-Retinoic Acid in Advanced Solid Tumor Malignancies. |
| 0C-05-6 | Phase I Study of Two Different Schedules of Lapatinib (GW572016) in Combination with Vinorelbine in Advanced Solid Tumors. |
| 0C-06-1 | A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients with Varying Degrees of Renal Function. |
| 0C-06-3 | A Phase I Study of Halichondrin B Analog (E7389) in Combination with Cisplatin in Advanced Solid Tumors. |
| 0C-06-6 | An Open-Label Extended-Use Study of Oral CEP-701 in Patients with Hematologic Malignancies Who Have Participated in a Clinical Study of CEP-701. |
| 0C-06-7 | A Phase I Biological Study of Intraveous Azacitidine (Vidaza) in Hematologic Malignancies. |
| 0C-06-8 | A Phase II Study of Temozolomide (SCH52365) in Subjects with Advanced Aerodigestive Tract Cancers Selected for Methylation of O6-Methyl-Guanine-DNA Methyltransferase (MGMT) Promoter. |
| 0C-07-1 | A Pharmacokinetic Study of BMS-582664 in Subjects with Advanced Solid Tumor Malignancies and Normal Hepatic Function or Hepatocellular Carcinoma with Impaired Hepatic Function. |
| 0C-07-2 | Phase I and Pharmacokinetic Study of Vorinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction. |
| 0C-07-3 | Phase I Trial of Abraxane Administered on a Weekly and Three Weekly Schedule in Combination with Vandetanib. |
| 0C-07-6 | A Multiple Center, Open-Label, Dose Escalation Study of the Safety and Pharmacokinetics of Oral NRX 194204 Capsule Administered Daily for a Minimum of 4 Weeks in Patients with Refractory Malignancies. |
| 0C-07-7 | A Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Advanced Solid Malignancies. |
| 0C-07-9 | A Phase I and Pharmacokinetic Single Agent Study of Pazopanib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction. |
| 0C-99-1 | Phase I Trial of 5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine. |
| 0C-99-10 | Phase I Study of Continuous Infusion of Topotecan Concurrent with Radiation for Locally Advanced Cervical Carcinoma. |
| 0C-99-7 | Phase I Clinical and Pharmacokinetic Trial of Intra-Peritoneal Irinotecan. |
| 0I-04-3 | A Pilot Trial to Determine the Safety and Immunologic Effects of Immature Dendritic Cells Injected into Hepatocellular Carcinoma and Ocular Malignant Melanoma Liver Metastases following Cryoablation. |
| 0I-05-2 | Open-Label Pharmacokinetic Trial of Aldesleukin (rh-Interleukin-2 [IL-2]) Administered Intravenously to Subjects with Metastatic Renal Cell Carcinoma or Metastatic Melanoma with Immunologic Correlative Studies. |
| 0S-00-11 | Blood Collection in Patients with Lung Cancer. |
| 0S-00-15 | Molecular Determinants of Response and Survival to Fluoropyrimidines in Patients with GI Cancer. |
| 0S-00-16 | Molecular Determinants of Response and Survival to Platinum Compounds (Oxaliplatin and Cisplatin) in Patients with Cancer. |
| 0S-01-17 | Tumor Tissue Collection for Molecular Determinants in Patients with Cancer Treated with Gemcitabine-Based Chemotherapy. |
| 0S-01-18 | Tumor Tissue Collection for Molecular Determinants in Patients with Cancer Treated with CPT-11-Based Chemotherapy. |
| 0S-03-2 | Comprehensive Tissue Repository: A Study of the Biology, Pathogenesis, Etiology, and Genetics of B-Cell and T-Cell Lymphoproliferative Disorders. |
| 0S-03-6 | Serum/Plasma Collection in Patients with GI Cancer and Healthy Volunteers. |
| 0S-04-3 | Transcriptome-Based Colorectal Tissue-Specific Microarrays as Predictors of Clinical Outcome in Patients with Metastatic and Locally Advanced Disease. |
| 0S-04-7 | USC Tumor and Tissue Bank. |
| 0S-05-3 | A Phase I/II Study to Evaluate the Safety and Preliminary Activity of Zarnestra (R115777, Tipifarnib) in Combination with Low-Dose Ara-C (LDAC) in Patient with Myelodysplastic Syndrome (MDS) and AML. |
| 0S-06-4 | A Randomized, Double-Blind, Placebo-Controlled Study of Apixaban for the Prevention of Thromboembolic Events in Patients Undergoing Treatment for Advanced Cancer: A Phase II Pilot Study |
| 0S-06-5 | Efficacy of Fine Needle Aspiration Biopsy versus Core Biopsy for Diagnosis of Soft Tissue Tumors. |
| 0S-07-3 | DNA Methylation and Epigenetic Analysis of Achival Cancer Samples. |
| 0S-08-1 | A Phase I Open Label Single Center Safety Study of [F-18] FLT. |
| 0S-08-5 | Multi-Center Database/Registry of Subjects at High Risk for Ovarian or Breast Cancer – A Lynne Cohen Consortium Project. |
| 0S-99-5 | Imaging of 11C-FMAU in Cancer. |
| 13NHL-05-2 | Phase II Trial of FavId (Patient-Specific Idiotype/KLH) and GM-CSF in Subjects Who Demonstrated Progressive Disease and Did Not Receive FavId on Study FavId-06. |
| 13NHL-05-3 | A Multi-Center Phase III Study to Investigate the Safety and Efficacy of Treanda (Bendamustine HCl) in Patients with Indolent Non-Hodgkin’s Lymphoma (NHL) who are Refractory to Rituximab. |
| 13NHL-06-1 | A Randomized, Multi-Center, Open-Label Study of Velcade with Rituximab or Rituximab Alone in Subjects with Relapsed or Refractory, Rituximab-Naïve or Sensitive Follicular B-Cell Non-Hodgkin’s Lymphoma. |
| 13NHL-06-2 | Randomized, Open-Label, Phase II Trial Comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-Cell Lymphoma. |
| 13NHL-06-3 | A Phase I/IIa Study Evaluating the Safety, Pharmacokinetics, and Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies. |
| 13NHL-06-4 | A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non-Hodgkin’s Lymphoma. |
| 13NHL-07-3 | Rituximab Plus CHOP Given Every Two Weeks with Sargramostim in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. |
| 16M-06-1 | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 (Humanized anti-CS1 Monoclonal IgG1 Antibody) in Subjects with Advanced Multiple Myeloma. |
| 16M-07-1 | A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Combination of CNTO 328 (Anti-IL-6 Monoclonal Antibody) and Velcade versus Velcade Alone in Subjects with Relapsed or Refractory Multiple Myeloma. |
| 18M-07-1 | Phase II Study of AZD2171 (NSC#732208) in Patients with Malignant Mesothelioma. |
| 1B-03-8 | Phase I-II Trial of ZD1839 (IRESSA), Trastuzumab (Herceptin), and Docetaxel (Taxotere) in Patients with erbB-2 (HER-2) Overexpressing, Stage IV Breast Carcinoma. |
| 1B-04-4 | An International Randomized Controlled Trial to Compare Targeted Intra-Operative Radiotherapy with Conventional Post-Operative Radiotherapy after Conservative Breast Surgery for Women with Early Stage Breast Cancer. |
| 1B-05-5 | Sonography Compared with MRI in Pre-Operative Evaluation of Patients with Breast Cancer to Determine Extent of Breast Disease. |
| 1B-06-10 | EphB4 Expression in Human Breast Cancer. |
| 1B-06-9 | Targeted Intra-Operative Radiotherapy for the Management of Ductal Carcinoma In-Situ of the Breast (TARGIT-DCIS Trial): Use of Mammography and Breast MRI to Identify Candidates for IORT. |
| 1B-08-1 | Pilot Study of Green Tea Supplement in Women with Ductal Carcinoma in Situ.
|
| 2N-04-3 | Phase II Study of Bortezomib (PS-341) for Patients with Advanced Bronchiolo-Alveolar Carcinoma (BAC) or Adenocarcinoma with BAC Features. |
| 2N-05-4 | A Phase III, Multi-Center, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination with Tarceva (Erlotinib) Compared with Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy. |
| 2N-05-6 | Randomized Phase II Trial of Sequential versus Concurrent Docetaxel and PS-341 (NSC 681239, IND 58,443) in Previously Treated Non-Small Cell Lung Cancer (NSCLC). |
| 2N-06-7 | A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Single-Agent Tarceva (Erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIA Non-Small Cell Lung Carcinoma who have EGFR-Positive Tumors. |
| 2N-06-8 | A Multi-Center, Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Cancer Vaccine Stimuvax (L-BLP25 or BLP25 Liposome Vaccine) in Non-Small Cell Lung Cancer (NSCLC) Subjects with Unresectable Stage III Disease. |
| 2N-06-9 | Randomized Phase II Study of Vorinostat or Placebo in Combination with Carboplatin and Paclitaxel for Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. |
| 2N-07-2 | Pilot Study of Changes in FDG- and FLT-PET Imaging in Patients with Non-Small Cell Lung Cancer Following Treatment with Erlotinib. |
| 2N-07-4 | An Open-Label, Randomized, Phase II Study of Efficacy and Tolerability of ABT-869 in Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC). |
| 2N-07-5 | A Phase I Dose Escalation and Pharmacokinetic Study of TG01 in Combination with Erlotinib in Non-Small Cell Lung Cancer Patients. |
| 3C-02-1 | Phase I Study of Xeloda and Gleevec in Patients with Advanced Solid Tumors. |
| 3C-03-19 | Phase I/II Study of Celebrex and EPO906 in Patients with Metastatic Colorectal Cancer (CEPO906AUS10). |
| 3C-04-10 | Phase II Study of Oxaliplatin, Capecitabine, and Bevacizumab as First-Line Treatment for Patients with Advanced Colorectal Cancer. |
| 3C-05-3 | Phase I/II Clinical Trial with Vorinostat and Infusional 5-FU/LV in Patients with Metastatic Colorectal Cancer who Failed 5-FU-Based Chemotherapy. |
| 3C-06-1 | A Pilot Study to Evaluate the Safety and Efficacy of Aprepitant in Combination with Dolasetron and Dexamethasone for the Prevention of Nausea and Vomiting Following Oxaliplatin-Containing Regimen Which Includes 5-FU. |
| 3C-06-2 | A Single Arm Phase II Study of the Efficacy, Safety, and Biomarkers of Activity of E7820 plus Cetuximab in Patients with Colorectal Cancer Preceded by a Run-In Study to Determine Safety of the Combination in Advanced Solid Tumors. |
| 3C-06-4 | A Randomized Phase II Study of Irinotecan Plus Cetuximab with or without Enzastaurin in Patients with Recurrent Colorectal Cancer. |
| 3C-06-5 | A Multi-Center, Open-Label, Randomized, Phase II Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects with Metastatic Colorectal Cancer. |
| 3C-07-3 | A Pilot Study of PPX (Paclitaxel Poliglumex, CT-2103) in Women with Metastatic Colorectal Cancer. |
| 3G-03-4 | Phase II Study of Oxaliplatin, Xeloda, and Cetuximab as First-Line Treatment for Metastatic or Unresectable Gastric or Gastroesophageal Junction Cancer. |
| 3G-03-5 | Phase II Study of Irinotecan and Docetaxel in Patients with Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma. |
| 3G-07-1 | A Randomized Phase II Study of Patients with Locally Advanced Gastric or Gastro-Esophageal Adenocarcinoma Treated with Induction Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Adjuvant Intraperitoneal Floxuridine Followed By Prolonged Administration of Capecitabine. |
| 3G-07-3 | Establishing Continuous Cell Lines and Xenografts from Adult Gastrointestinal Cancers and Inflammatory Bowel Disease for Biological and Pre-Clinical Therapeutic Studies. |
| 3G-07-4 | Transcriptome-Based Microarrays as Predictors of Clinical Outcome in Patients with Metastatic and Locally Advanced Gastrointestinal Cancers. |
| 3G-07-5 | A Phase II Study Trastuzumab (NSC 688097) in Her2/neu Positive Cancer of the Gallbladder or Biliary Tract. |
| 3G-07-6 | A Double-Blind, Randomized, Multi-Center, Phase III Study of Bevacizumab in Combination with Capecitabine and Cisplatin versus Placebo in Combination with Capecitabine and Cisplatin, as First-Line Therapy in Patients with Advanced Gastric Cancer. |
| 3L-03-1 | A Phase II Study of Intra-Arterial Chemotherapy with Cisplatin and Mitomycin-C in Patients with Hepatocellular Carcinoma. |
| 3L-06-3 | A Phase II Trial of Dasatinib (BMS-354825) in Advanced Hepatocellular Carcinoma. |
| 3P-07-3 | A Randomized Phase II/III Study of TNFerade Biologic with 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer. |
| 4B-01-2 | A Randomized Comparison of the Studer Pouch vs. the T-Pouch Orthotopic Neobladder Urinary Diversion in Bladder Cancer Patients. |
| 4B-06-1 | A Phase I/II Study of E7389 Halichondrin B Analog (NSC #707389; IND #64395) in Metastatic Urothelial Tract Cancer and Renal Insufficiency. |
| 4B-06-3 | A Randomized Phase II Study of Docetaxel +/- ZD6474 (Zactima) in Metastatic Transitional Cell Carcinoma. |
| 4B-07-1 | A Multi-Center Study to Obtain Bladder Tissue Specimens from Subjects Undergoing Transurethral Resection of Bladder Tumor (TURBT) or Other Transurethral Biopsy Procedure. |
| 4K-04-1 | A Randomized Phase II Study of VEGF-Antisense Oligonucleotide (VEGF-AS) in Advanced Renal Cell Carcinoma. |
| 4K-05-1 | Phase I/II Trial of Bortezimib and Bevacizumab (“BB-mib-mab”) in Patients with Advanced or Recurrent Renal Cell Cancer (RCC) with Assessment of Tissue Correlates of Response. |
| 4K-06-6 | A Phase I/II, Open-Label, Dose Escalation Study to Assess the Safety and Pharmacokinetics of Recombinant Interleukin 21 (rIL-21) Administered Concomitantly with Sorafenib (Nexavar) in Subjects with Metastatic Renal Cell Carcinoma. |
| 4P-04-3 | A Phase II Study of PS-341 (Velcade, Bortezomib) and Docetaxel for Patients with Hormone-Refractory Prostate Cancer. |
| 4P-05-1 | FDG PET-CT in Metastatic Prostate Cancer. |
| 4P-05-7 | A Phase II Trial of Oxaliplatin and Pemetrexed in Hormone Refractory Prostate Cancer. |
| 4P-06-2 | Phase II Trial of Oral Enzastaurin in Prostate Cancer Patients Who Have Rising PSA (1) During Hormonal Manipulation, and (2) After First-Line Cytotoxic Chemotherapy. |
| 4P-06-4 | Docetaxel (Taxotere) plus 6-Month Androgen Suppression and Radiation Therapy vs. 6-Month Androgen Suppression and Radiation Therapy for Patients with High-Risk Localized or Locally Advanced Prostate Cancer: A Randomized Controlled Trial. |
| 4P-06-6 | Prospective Evaluation of TargetScan Guided Prostate Needle Biopsy By Creation of a Multi-Center Data Registry. |
| 4T-03-1 | A Phase II Study of Gemcitabine, Oxaliplatin, and Paclitaxel in Patients with Refractory Germ Cell Carcinoma. |
| 5GYN-06-1 | A Pilot Phase II Study Evaluating the Combination of Oxaliplatin and Docetaxel with Bevacizumab as First-Line Therapy in Patients with FIGO Stage IB-IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma. |
| 5GYN-06-2 | A Randomized, Parallel Group, Open-Label, Active Controlled, Multi-Center Phase III Trial of Patupilone (EPO906) versus Pegylated Liposomal Doxorubicin (Doxil/Caelyx) in Taxane/Platinum-Refractory/Resistant Patients with Recurrent Epithelial Ovarian, Primary Fallopian, or Primary Peritoneal Cancer. |
| 5GYN-06-3 | A Phase II Study of VEGF Trap in Recurrent or Metastatic Gynecologic Soft Tissue Sarcomas. |
| 5GYN-06-4 | A Phase II Study of AZD2171 in Patients with Recurrent or Persistent Ovarian, Peritoneal, or Fallopian Tube Cancer. |
| 5GYN-06-5 | An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 every 21 days) Hycamtin in Combination with Carboplatin (Day 1 every 21 days) as Second-Line Therapy in Subjects with Potentially Platinum-Sensitive Relapsed Ovarian Cancer. |
| 5O-04-1 | Serum Proteomics: For Detection of Ovarian Cancer Using the Correlogic Systems, Inc. Serome Pattern Blood Test System. |
| 6B-07-2 | A Phase III Randomized, Double-Blind, Dexamethasone-Sparing Study Comparing Human Corticotropin-Releasing Factor (hCRF) to Placebo for Control of Symptoms Associated with Peritumoral Brain Edema in Patients with Malignant Brain Tumor Who Require Chronic Administration of High-Dose Dexamethasone. |
| 6B-07-3 | An Open-Label, Extended-Use Study of Human Corticotropin-Releasing Factor (hCRF) Intended for Patients who Participate in the Dexamethasone-Sparing Studies NTI 0302, NTI 0303, or Other Designated Studies. |
| 7H-05-1 | A Phase III Randomized Trial of Docetaxel-Based Induction Chemotherapy in Patients with N2/N3 Locally Advanced Head and Neck Cancer (DeCIDE Trial). |
| 7H-07-1 | A Multi-Center, Open-Label, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate (CA4P) in Combination with Paclitaxel and Carboplatin in Comparison with Paclitaxel and Carboplatin Against Anaplastic Thyroid Carcinoma. |
| 9L-03-1 | Treatment of Newly Diagnosed Adult Acute Lymphoblastic Leukemia with Intensified Post-Remission Therapy Containing PEG-Asparaginase. |
| 9L-04-3 | A Phase III Randomized Study of Cloretazine (VNP40101M) and Cytosine Arabinoside (Ara-C) in Patients with Acute Myeloid Leukemia in First Relapse. |
| 9L-05-2 | A Pivotal Randomized Study of Lonafarnib (SCH66336) Versus Placebo in the Treatment of Subjects With Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Who are Platelet Transfusion-Dependent With or Without Anemia. |
| 9L-05-4 | A Randomized, Open-Label Study of Oral CEP-701 Administered in Sequence with Standard Chemotherapy to Patients with Relapsed Acute Myeloid Leukemia (AML) Expressing FLT-3 Activating Mutations. |
| 9L-06-1 | A Phase III Randomized, Double-Blind, Controlled Study Comparing Clofarabine and Cytarabine versus Cytarabine Alone in Adult Patients 60 Years or Older with Acute Myelogenous Leukemia (AML) who have Relapsed or are Refractory after Receiving up to Two Prior Induction Regimens. |
| 9L-06-4 | A Phase II Open-Label Study of the Subcutaneous Administration of Homoharringtonine (CGX-635) in the Treatment of Patients with Chronic Myeloid Leukemia (CML) with the T315I BCR-ABL Gene Mutation. |
| 9L-06-5 | A Phase II Study of Cloretazine for Elderly Patients with DE NOVO Poor Risk Acute Myelogenous Leukemia. |
| 9L-06-7 | An Open-Label Randomized Phase III Study of Dasatinib vs. Standard-Dose (400 mg) Imatinib Mesylate in the Treatment of Subjects with Chronic Phase Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Have Had a Suboptimal Response After 3-12 Months of Therapy with >/= 400 mg Imatinib. |
| 9L-07-1 | A Phase II Study to Evaluate the Safety and Efficacy of Weekly Doses of Marqibo (vincristine sulfate liposomes injection) in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Adult Patients with Philadelphia Chromosome-Negative ALL Who Failed Two Treatment Lines of Anti-Leukemia Chemotherapy. |
| 9L-07-10 | An Open-Label, Randomized Study of Low-Dose Cytarabine in Combination with Arsenic Trioxide Compared with Low-Dose Cytarabine Alone for the Treatment of Elderly Patients with Acute Myeloid Leukemia. |
| 9L-07-4 | Phase I and Pharmacodynamic Study of GTI-2040 (NSC 722929, IND 67368) in Acute Leukemias. |
| 9L-07-5 | A Phase III, Randomized, Double-Blind, Multi-Center Study of Proteinase 3 PR1 Peptide Mixed with Montanide ISA 51 VG Adjuvant and Administered with GM-CSF in Elderly Patients with AML in First Complete Remission or Adults in Second Complete Remission: A Pivotal Study. |
| ACRIN6668/Rtog-0235 | Positron Emission Tomography (PET) Pre- and Post-Treatment Assessment for Locally Advanced Non-Small Cell Lung Carcinoma. |
| AMC-047 | A Phase II Trial of Doxil, Rituximab, Cyclophosphamide, Vincristine, and Prednisone (DR-COP) in Patients with Newly Diagnosed AIDS-Associated B-Cell Non-Hodgkin’s Lymphoma. |
| AMC-048 | Prospective Phase II Study of a High Dose, Short Course Regimen (R-CODOX-M/IVAC) including CNS Penetration and Intensive IT Prophylaxis in HIV-Associated Burkitt’s and Atypical Burkitt’s Lymphoma. |
| ctsu/AcosogZ1031 | A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25 mg daily), Letrozole (2.5 mg), or Anastrozole (1 mg) in Post-Menopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer. |
| ctsu/Calgb40101 | Cyclophosphamide and Doxorubicin (CA x 4 cycles) versus Paclitaxel (4 cycles) as Adjuvant Therapy for Breast Cancer in Women with 0-3 Positive Axillary Lymph Nodes: A Phase III Randomized Study. |
| ctsu/Calgb80405 | A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum. |
| ctsu/Calgb90203 | A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer. |
| ctsu/E1505 | A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (=/>4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC). |
| ctsu/E2805 | Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma. |
| ctsu/E5204 | Intergroup Randomized Phase III Study of Post-Operative Oxaliplatin, 5-Fluorouracil, and Leucovorin vs. Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation. |
| ctsu/Ecog/PACCT-1 | Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial. |
| ctsu/Ibcsg2402 | A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Pre-Menopausal Women with Endocrine Responsive Breast Cancer |
| ctsu/Ncctg/N0434/MA27D | The Association of Breast Density Changes, Plasma Hormone Changes, and Breast Cancer Recurrence: A Companion Study to NCIC CTG MA.27. |
| ctsu/NcicCtgMA27 | A Randomized Phase III Trial of Exemestane versus Anastrozole in Post-Menopausal Women with Receptor Positive Primary Breast Cancer. |
| ctsu/NcicCtgMA27B | The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density in Post-Menopausal Women with Primary Breast Cancer. A Companion Study to NcicCtgMA27. |
| ctsu/NsabpB42 | A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Post-Menopausal Women with Hormone Receptor Positive Breast Cancer. |
| GOG-0205 | A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva. |
| GOG-0206 | Lymphatic Mapping and Sentinel Node Identification in Patients with Stage IB1 Cervical Carcinoma. |
| GOG-0218 | A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC #704865, IND #7921) Followed by Placebo, versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Stage III (Suboptimal) and all Stage IV, Epithelial Ovarian or Primary Peritoneal Cancer. |
| GOG-0239 | A Phase II Trial of AZD6244 (NSC #741078, IND #77782) in Women with Recurrent Low Grade Serous Carcinoma of the Ovary. |
| NSABP-R04 | A Clinical Trial Comparing Pre-Operative Radiation Therapy and Capecitabine With or Without Oxaliplatin With Pre-Operative Radiation Therapy and Continuous Intravenous Infusion of 5-Fluorouracil With or Without Oxaliplatin in the Treatment of Patients with Operable Carcinoma of the Rectum. |
| RTOG-0229 | A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and High-Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy for Locally Advanced Non-Small Cell Lung Carcinoma. |
| RTOG-0413 | A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer. |
| RTOG-0513 | A Phase I/II Trial of Temozolomide, Motexafin Gadolinium, and 60 Gy Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme. |
| RTOG-0517 | Randomized Phase III Trial to Evaluate RadioPharmaceuticals and Zoledronic Acid in the Palliation of Osteoblastic Metastases from Lung, Breast, and Prostate Cancer. |
| RTOG-0518 | A Phase III, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Zometa for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long-Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer. |
| RTOG-0522 | A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck Carcinomas. |
| SWOG-9007 | Cytogenetic Studies in Leukemia Patients. |
| SWOG-E1697 | Phase III Randomized Study of Four Weeks of High-Dose IFN-a2b in Stage T2b N0, T3a-b, T4a-b N0, and T1-4 N1a, 2a, 3 (Microscopic) Melanoma. |
| SWOG-JMA17R | A Double-Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the JMA.17 Study) (Sub-Study of SWOG-JMA17). |
| SWOG-S0106 | A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg) During Induction Therapy versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed by Consolidation and Subsequent Randomization to Post-Consolidation Therapy with Gemtuzumab Ozogamicin (Mylotarg) or No Additional Therapy for Patients Under Age 61 with Previously Untreated DeNovo Acute Myeloid Leukemia (AML). |
| SWOG-S0221 | Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer. |
| SWOG-S0230 | Phase III Trial of LHRH Analog Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer. |
| SWOG-S0307 | Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. |
| SWOG-S0309 | Myeloma Specimen Repository Protocol, Ancillary. |
| SWOG-S0325 | A Phase IIB Study of Molecular Responses to Imatinib at Standard or Increased Doses, or Dasatinib (BMS-354825) (NSC-732517) for Previously Untreated Patients with Chronic Myelogenous Leukemia (CML) in Chronic Phase. |
| SWOG-S0337 | A Phase III Blinded Study of Immediate Post-TURBT Instillation of Gemcitabine versus Saline in Patients with Newly Diagnosed or Occasionally Recurring Grade I/II Superficial Bladder Cancer. |
| SWOG-S0353 | Phase II Study of Intravesical Gemcitabine in Patients with Superficial Bladder Cancer who have Progressed Despite Intravesical BCG. |
| SWOG-S0421 | Phase III Study of Docetaxel and Atrasentan versus Docetaxel and Placebo for Patients with Advanced Hormone Refractory Prostate Cancer. |
| SWOG-S0429 | A Pilot (Phase I) Study of Weekly Docetaxel and Cetuximab Chemoradiation for Poor Risk Stage III Non-Small Cell Lung Cancer. |
| SWOG-S0438 | A Randomized Phase II Trial of BAY 43-9006 (Sorafenib; NSC-724772) with Either CCI-779 (Temsirolimus; NSC-683864) or R115777 (Tipifarnib; NSC-702818) in Metastatic Melanoma. |
| SWOG-S0500 | A Randomized Phase III Trial to Test the Strategy of Changing Therapy versus Maintaining Therapy for Metastatic Breast Cancer Patients Who Have Elevated Circulating Tumor Cell Levels at First Follow-up Assessment. |
| SWOG-S0518 | Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis Carcinoid Patients. |
| SWOG-S0526 | Phase II Trial of Pemetrexed in Patients with Selected Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC). |
| SWOG-S9910 | Leukemia Centralized Reference Laboratories and Tissue Repositories, Ancillary. |
| SWOG-S9925 | Lung Cancer Specimen Repository Protocol, Ancillary. |
